株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

緑内障手術装置の世界市場

2019 Glaucoma Surgical Device Market Report: A Global Analysis for 2018 to 2024

発行 Market Scope, LLC 商品コード 644809
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
緑内障手術装置の世界市場 2019 Glaucoma Surgical Device Market Report: A Global Analysis for 2018 to 2024
出版日: 2019年08月14日 ページ情報: 英文
概要

当レポートでは、世界の緑内障手術装置市場について調査し、有病率と予測、外科的介入の役割、現在市販されている製品の市場ダイナミクス、および転帰の改善をもたらすと見られる研究段階にある装置のパイプラインなどの分析を提供しており、製品需要の予測 (数量ベース・金額ベース) 、製品分類別の市場シェア分析、主な戦略的課題に関する議論などをまとめています。

イントロダクション

エグゼクティブサマリー

緑内障について

緑内障の有病率

緑内障の治療プロバイダー

  • プロバイダー、診断、治療の概要
  • 治療プロバイダーおよび診断施設
  • 米国のプロバイダー
  • 西欧のプロバイダー
  • 日本のプロバイダー、ほか

緑内障の診断

  • 眼圧測定
  • 角膜厚測定
  • 視野測定
  • 検眼鏡検査
  • 眼底撮影
  • 光コヒーレンストモグラフィー (OCT)
  • 共焦点走査型レーザー検眼鏡、ほか

緑内障の治療

  • 治療法
  • 処方薬
  • 開放隅角緑内症の治療
  • 高眼圧症患者におけるIOP治療
  • 剥離性緑内障/疑似紅斑緑内障の治療
  • 閉塞隅角緑内障
  • 現在の薬物療法の限界
  • 緑内障専門医への紹介
  • レーザーと外科手術、ほか

緑内障管理の課題

  • IOPの主な役割
  • IOPおよび緑内障に関する競合理論
  • 緑内障治療選択肢の広がり
  • 眼科医が最善のPOAG治療選択肢を決定する方法
  • POAGステージおよび典型的な治療アプローチ

レーザー製品

  • レーザー線維柱帯形成術
  • アルゴンレーザー線維柱帯形成術 (ALT)
  • 選択的レーザー線維柱帯形成術 (SLT)
  • 線維柱帯形成術による薬物療法の削減
  • マルチレーザー治療法の頻度
  • レーザー周辺虹彩切開術 (PI)
  • 隅角形成術 (虹彩形成) 、ほか

緑内障の外科手術治療

  • 世界の緑内障外科手術:国/地域別
  • 緑内障外科手術のロケーション
  • 世界の緑内障外科手術予測
  • 外科治療済み緑内障患者人口比率の増加

従来型の緑内障外科手術 (CGS)

  • ろ過手術 (線維柱帯切除術)
  • 線維柱帯切除術の効果に関するデータ
  • ろ過手術の種類・数量
  • 医療費償還

線維柱帯切除術の付属製品

白内障手術のIOP (眼圧) 低下硬化

緑内障外科手術装置の先進技術

低侵襲緑内障外科手術 (MIGS) ステント

管手術装置

  • 規制状況
  • (緑内障手術) 管形成術
  • 近年の治験結果
  • 規制、医療費償還および市況
  • 管形成術製品の予測、ほか

線維柱帯切除 (Trab) プラス装置

  • 臨床結果
  • その他の緑内障外科手術装置

シングルユーズアイテム

  • シングルユーズアイテムの市場予測
  • 競合企業

再利用可能外科手術装置・ナイフ

企業プロファイル

目次

What's New:

‘The 2019 Glaucoma Surgical Device Market Report’ includes a new section on devices that deliver sustained release of medications and a deep dive analysis of the Alcon CyPass recall that occurred in 2018 and its impact on adoption of minimally invasive glaucoma surgery (MIGS) stents.

‘The 2019 Glaucoma Surgical Device Market Report’ offers a comprehensive analysis of the 2019 global market for glaucoma devices, as well as a discussion of important trends and key factors shaping future success. The report examines the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. Product demand is forecast in units and dollars, and market shares are analyzed by product category.

Also in this report:

  • Deep dive analysis of the Alcon CyPass recall that occurred in 2018 and its impact on adoption of minimally invasive glaucoma surgery (MIGS) stents
  • We divide the 4 basic surgery categories into 15 different product types which are profiled
  • Analysis on the percentage of the different types of glaucoma surgeries being performed by US cataract surgeons, glaucoma specialists, and general ophthalmologists
  • New section on key opinion leaders' decision making on glaucoma surgery options
  • Background information about glaucoma, glaucoma populations, and glaucoma diagnosis
  • Estimates of current sales and sales forecasts for glaucoma devices, including average prices and total revenue.
  • Profiles of prospective device buyers, including ophthalmologists, ophthalmic specialists, optometrists, and general medical doctors
  • Information about manufacturers
  • Current reimbursement rates
  • Updated total global glaucoma populations for POAG, PACG, secondary and pediatric glaucoma, and ocular hypertension in eight regions

The report also simplifies the glaucoma surgery categories to four (MIGS, TRABs, tubes, and canal surgery), identifies the MIGS pipeline stents that will drive surgery penetration in each of the stages of glaucoma, and lists 15 early-stage glaucoma surgery device development projects.

Our Process:

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

  • Our proprietary global disease population and demographic models
  • Analysis of company-published financial reports
  • Focused coverage of ophthalmic scientific research, business news, and other activities
  • Attendance and participation in worldwide ophthalmic meetings
  • Interviews and relationships with company executives and practicing physicians

Author Profile:

William Freeman

Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.

Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.

CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.

In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.

Bill remained with Alcon until 1995. He then joined Mentor Ophthalmics as president of the ophthalmology division. At Mentor, he was responsible for the company's ophthalmic products including IOLs, cautery devices, and surgical instruments.

After leaving Mentor in 1999, Bill joined Market Scope in 2000 and now serves as executive vice president focusing on ophthalmic surgical cataract, retinal and glaucoma devices.

Back to Top